Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
MicroRNAs (miRNAs) regulate mRNA stability and protein expression, and certain miRNAs have been demonstrated to act either as oncogenes or tumor suppressors. Differential miRNA expression signatures have been documented in many human cancers but the role of miRNAs in endometrioid
endometrial cancer
(
EEC
) remains poorly understood. This study identifies significantly dysregulated miRNAs of
EEC
cells, and characterizes their impact on the malignant phenotype. We studied the expression of 365 human miRNAs using Taqman low density arrays in EECs and normal endometriums. Candidate differentially expressed miRNAs were validated by quantitative real-time PCR. Expression of highly dysregulated miRNAs was examined in vitro through the effect of anti-/pre-miRNA transfection on the malignant phenotype. We identified 16 significantly dysregulated miRNAs in
EEC
and 7 of these are novel findings with respect to
EEC
. Antagonizing the function of miR-7, miR-194 and miR-449b, or overexpressing miR-204, repressed migration, invasion and extracellular matrix-adhesion in HEC1A
endometrial cancer
cells.
FOXC1
was determined as a target gene of miR-204, and two binding sites in the 3'-untranslated region were validated by dual luciferase reporter assay.
FOXC1
expression was inversely related to miR-204 expression in
EEC
. Functional analysis revealed the involvement of
FOXC1
in migration and invasion of HEC1A cells. Our results present dysfunctional miRNAs in
endometrial cancer
and identify a crucial role for miR-204-
FOXC1
interaction in
endometrial cancer
progression. This miRNA signature offers a potential biomarker for predicting
EEC
outcomes, and targeting of these cancer progression- and metastasis-related miRNAs offers a novel potential therapeutic strategy for the disease.
...
PMID:Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. 2140 May 11
MicroRNAs (miRNAs) are a class of noncoding RNAs and function as key regulators of gene expression at the post-transcriptional level. In this study, we found that miR-495 reduces cell growth, induces apoptosis and suppresses the migration of
endometrial cancer
by directly inhibiting
FOXC1
expression. Further analysis revealed that
FOXC1
promotes growth and migration and functions as an oncogene in vitro.
FOXC1
overexpression reversed the cellular responses mediated by miR-495 in
endometrial cancer
cells. We also found that miR-495 suppresses the growth of
endometrial cancer
in vivo. Altogether, these results indicate that miR-495 acts as a tumour suppressor gene by targeting
FOXC1
at the post-transcriptional level in
endometrial cancer
.
...
PMID:MicroRNA-495 downregulates FOXC1 expression to suppress cell growth and migration in endometrial cancer. 2619 45
In recent years, rapidly accumulating evidence implicates forkhead box C1 (
FOXC1
) in cancer, especially in studies of basal-like breast cancer (BLBC). Other studies have followed suit, demonstrating that
FOXC1
is not only a major player in this breast cancer subtype, but also in hepatocellular carcinoma (HCC),
endometrial cancer
, Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL). The
FOXC1
gene encodes a transcription factor that is crucial to mesodermal, neural crest, and ocular development, and mutations found in
FOXC1
have been found to cause dominantly inherited Axenfeld-Rieger Syndrome (ARS). Interestingly, while
FOXC1
missense mutations that are associated with ARS usually reduce gene activity, increased
FOXC1
function now appears to be often linked to more aggressive cancer phenotypes in BLBC, HCC, HL, and NHL. This review discusses not only the role of
FOXC1
in cancer cell progression, proliferation, differentiation, and metastasis, but also the underlying mechanisms of how
FOXC1
can contribute to aggressive cancer phenotypes.
...
PMID:FOXC1, the new player in the cancer sandbox. 2948 24